Validation of the patient activation measure in a multiple sclerosis clinic sample and implications for care

Disability and Rehabilitation

Volumn 32, Issue 19, 2010, Pages 1558-1567

  Stepleman, Lara ^a   Rutter, Marie Christine ^a   Hibbard, Judith ^b   Johns, Lisa ^a   Wright, Dustin ^c   Hughes, Mary ^d  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF OREGON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d GREENVILLE HOSPITAL SYSTEM   (United States)

Author keywords

illness behaviour; Multiple sclerosis; patient activation; patient compliance; self efficacy

Indexed keywords

ANALYSIS OF VARIANCE; ARTICLE; ATTITUDE TO HEALTH; DEPRESSION; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PATIENT PARTICIPATION; QUALITY OF LIFE; QUESTIONNAIRE; SELF CONCEPT; VALIDATION STUDY;

ANALYSIS OF VARIANCE; DEPRESSION; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; PATIENT PARTICIPATION; QUALITY OF LIFE; QUESTIONNAIRES; SELF EFFICACY;

EID: 77955066029     PISSN: 09638288     EISSN: 14645165     Source Type: Journal    
DOI: 10.3109/09638280903567885     Document Type: Article

References (50)

1. Berger B, Hudmon K, Liang L. Predicting treatment discontinuation among patients with multiple sclerosis: application of the transtheoretical model of change. J Am Pharm Assoc 2004;44:445-454.
2. Holland N, Wiesel P, Cavallo P, Edwards C, Halper J, Kalb R, Morgante L, Namey M, O?Leary M, Smith-Williamson L. Adherence to disease-modifying therapy in multiple sclerosis: part I. Rehabil Nurs 2001;26:172-176.
3. Crayton H, Rossman H. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Therapeut 2006;28: 445-460.
4. Romberg A, Ruutiainen J, Puukka P, Poikkeus L. Fatigue in multiple sclerosis patients during inpatient rehabilitation. Disabil Rehabil 2008;30:1480-1485.
5. O?Rourke K, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 2005;11:46-50.
6. Mohr D, Boudewyn A, Likosky W, Levine E, Goodkin D. Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectaions and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23:125-132.
7. Turner A, Kivlahan D, Sloan A, Haselkorn J. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model. Mult Scler 2007; 13:1146-1152.
8. Hibbard J, Stockard J, Mahoney E, Tusler M. Development of the patient activation measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res 2004;39:1005-1026.
9. Mosen D, Schmittdiel J, Hibbard J, Sobel D, Remmers C, Bellows J. Is patient activation associated with outcomes of care for adults with chronic conditions? J Ambul Care Manage 2007;30:21-29.
10. Hibbard J, Mahoney E, Stock R, Tusler M. Self-management and health care utilization; do increases in patient activation result in improved self-management behaviors? Health Serv Res 2007;42:1443-1463.
11. Naik A, Kallen M, Walder A, Street R. Improving hypertension control in diabetes mellitus: the effects of collaborative and proactive health communication. Circulation 2008;117: 1361-1368.
12. Manias E, Williams A. Managing pain in chronic kidney disease: patient participation in decision-making. J Adv Nurs 2008;61:201-210.
13. Marvel K, Epstein R, Flowers K, Beckman H. Soliciting the patient?s agenda: have we improved? J Am Med Assoc 1999; 282:283-287.
14. Street R, Gordon H, Ward M, Krupat E, Kravitz R. Patient participation in medical consultations: why some patients are more involved than others. Med Care 2005;43:960-969.
15. Street R. Communicative styles and adaptations in physicianparent consultations. Soc Sci Med 1992;34:1155-1163.
16. Rost K, Flavin K, Cole K, McGill J. Change in metabolic control and functional status after hospitalization. Impact of patient activation intervention in diabetic patients. Diabetes Care 1991;14:881-889.
17. Hollman H, Lorig K. Patients as partners in managing chronic illness. BMJ 2000;320:526-527.
18. Cox D, Stone J. Managing self-injection difficulties in patients with relapse-remitting multiple sclerosis. J Neurosci Nurs 2006;38:167-171.
19. Frohman E, Phillips T, Kokel K, Van Pelt J, O?Leary S, Gross S, Hawker K, Racke M. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227-236.
20. Blaney B E, Lowe-Strong A. The impact of fatigue on communication in multiple sclerosis. The insider?s perspective. Disabil Rehabil 2009;31:170-180.
21. McAuley E, Motl R, Morris K, Hu L, Doerksen S, Elavsky S, Konopack J. Enhancing physical activity adherence and wellbeing in multiple sclerosis: a randomized controlled trial. Mult Scler 2007;13:652-659.
22. Wassem R. Self-efficacy as a predictor of adjustment to multiple sclerosis. J Neurosci Nurs 1992;24:224-229.
23. Barnwell A, Kavanagh D. Prediction of psychological adjustment in multiple sclerosis. Soc Sci Med 1997;45:411-418.
24. Wingerson N, Wineman M. The mental health, self-efficacy, and satisfaction outcomes of a community counseling demonstration project for multiple sclerosis clients. J Appl Rehabil Counsel 2000;31:11-17.
25. Thorton E, Tedman S, Rigby S, Bashforth H, Young C. Worries and concerns of patients with MS: development of an assessment scale. Mult Scler 2006;12:196-203.
26. Minden L, Schifrer R. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Neurology 1990;4:98-104.
27. Minden L, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426-434.
28. D?Alisa S, Miscio G, Bando S, Simone A, Mauro A. Depression is the main determinant of quality of life in multiple sclerosis: a classification- regression (CART) study. Disabil Rehabil 2006;28:307-314.
29. Schiffer R, Babigan H. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. Arch Neurol 1984;41:1067-1069.
30. Wallbridge H, Furer P, Lionberg C. Behavioral activation and rehabilitation. J Psychosoc Nurs Ment Health Serv 2008;46: 36-45.
31. Mohr D, Goodkin D, Gatto N, Van Der Wende J. Depression coping and level of neurological impairment in multiple sclerosis. Mult Scler 1997;3:254-258.
32. Wineman N, Durand D, McCulloch B. Examination of the factor structure of the ways of coping questionnaire with clinical populations. Nurs Res 1994;43:268-273.
33. Smith AB, Rush R, Fallowfield LJ, Velikova G, Sharpe M. Rasch fit statistics and sample size considerations for polytomous data. BMC Med Res Meth 2008;8:33.
34. Franchignoni F, Girodano A, Ferriero G. Rasch analysis of the short form 8-item Parkinson?s disease Questionnaire (PDQ-8). Qual Life Res 2008;17:541-548.
35. Skolasky RL, Mackenzie EJ, Wegener ST, Riley LH. Patient activation and adherence to physical therapy in persons undergoing spine surgery. Spine 2008;33:E784-E791.
36. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. Health Serv Res 2005;40:1918-1930.
37. Beck AT, Steer RA, Brown GK. BDI-II, Beck depression inventory manual, 2nd ed. San Antonio, TX: Psychological Corp.; 1996.
38. Schwartz C, Coulthard-Morris L, Zeng Q, Retzlaff P. Measuring self-efficacy in people with multiple sclerosis: a validation study. Arch Phys Med Rehabil 1996;77:394-398.
39. Ford HL, Gerry E, Tennant A, Whalley D, Haigh R, Johnson MH. Developing a disease-specific quality of life measure for people with multiple sclerosis. Clin Rehabil 2001;15:247-258. (Pubitemid 32475720)
40. Hibbard JH, Cunningham P. How engaged are consumers in their health and health care and why does it matter? Washington, DC.: Research Brief, Center for Studying Health System Change. 2008.
41. Linacre JM. Optimizing rating scale category effectiveness. J Appl Meas 2002;3:85-106.
42. Wright BD, Masters GN. Rating scale analysis. Rasch analysis. Chicago: MESA Press, 1982.
43. Wright BD, Linacre JM. Reasonable mean-square fit values. Rasch Meas Trans 1994;8:370.
44. Minden SL, Frankel D, Hadden L, Perloff J, Srinath KP, Hoaglin DC. The Sonya Slifka longitudinal multiple sclerosis study: methods and sample characteristics. Mult Scler 2006; 12:24-38.
45. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol 2006;253:219-223.
46. Thomas PW, Thomas S, Hillier C, Galvin K, Baker R. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006;1. (DOI: 10.1002/14651858.CD 004431.pub2).
47. Wallin MT, Wilken JA, Turner AP, Williams RM, Kane R. Depression and multiple sclerosis: review of a lethal combination. J Rehabil Res Dev 2006;43:45-62.
48. Ennis M, Thain J, Boggild M, Baker GA, Young CA. A randomized controlled trial of a health promotion education programme for people with multiple sclerosis. Clin Rehabil 2006;20:783-792.
49. Hamann J, Neuner B, Kasper J, Vodermaier A, Loh A, Deinzer A, Heesen C, Kissling W, Busch R, Schmieder R, Spies C, Caspari C, Härter M. Participation preferences of patients with acute and chronic conditions. Health Expect 2007;10:358-363.
50. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing- remitting multiple sclerosis. Eur Neurol 2008;59:131-135.